LEO Pharma is expanding upon its ambitions in the United States (U.S.) as the FDA has accepted for filing the company’s New Drug Application (NDA) for delgocitinib cream, an investigational innovative ...

LEO Pharma A/S, a global leader in medical dermatology, today presented two late-breaking delgocitinib cream presentations for Chronic Hand Eczema (CHE), showcasing the findings for the DELTA TEEN ...

LEO Pharma A/S, a global leader in medical dermatology, has today announced submission of the New Drug Application (NDA) to the National Medical Products Administration (NMPA) in China for Anzupgo® ...

The out-licensing agreement will result in Hyphens Pharma receiving an upfront fee and customary royalties on sales.

Hyphens Pharma International Limited ('Hyphens Pharma', or the 'Company', and together with its subsidiaries, the 'Group'), Singapore's leading specialty pharmaceutical and consumer healthcare group, ...

The latest update is out from Hyphens Pharma International Ltd. ( ($SG:1J5) ). Hyphens Pharma International has entered into a licensing, supply ...